

\*\*\*\*Published May 2023\*\*\*\*

## MarketVIEW: Herpes Simplex virus therapeutic vaccines (CAT: VAMV038)

<b>Product Name</b>	:	<b>MarketVIEW: Herpes Simplex Virus (HSV) therapeutic vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation (>175 slides.pdf) + forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	<b>New adolescent/STI vaccines</b>
<b>Publication date</b>	:	May 2023
<b>Catalogue No</b>	:	VAMV038

### Background

**Herpes Simplex Virus (HSV-1/2)** are ubiquitous members of the human herpes family and are transmitted by oral/genital contact. Both viruses cause lifelong oral/ocular and/or genital infections (GUD). Although most individuals infected with HSV-1/2 have minimal signs of infection, persons with GUD can experience frequent disease reactivation which have a considerable impact on sexual reproductive health and wellbeing. Neonatal herpes, although rare, can have devastating consequences for the new-born infant with a mortality rate of ~60-85%. The WHO has estimated that 491m persons in 2016 were living with HSV-2 globally (15-49 yrs) which is 13.2% prevalence in this age group. HSV-1 is estimated to infect 3.7 bn people worldwide. HSV-2 is also a significant contributor to global HIV incidence especially in low-income countries.

Antiviral treatments e.g., **acyclovir** do exist for HSV infections and are designed to prevent symptomatic disease, improve quality of life and suppress the virus to prevent transmission to sexual partners. A **HSV-2 therapeutic vaccine** that can suppress symptomatic disease and prevent transmission could have great utility in infected populations and bring benefits via more convenient administration profile/long-lived protection. With new mRNA-focused vaccine competitors such as **ModernaTX** and **BioNTECH** now involved with HSV vaccines e.g., **mRNA-1608**, a renewed interest in therapeutic vaccine development is expected. GSK has also initiated a Phase 1/2 study with **GSK3943104A**

This **MarketVIEW** product is a comprehensive Executive Presentation (>175 slides, .pdf) and interactive MS-Excel forecast model which investigate the scenario-based interplay and commercial potential of HSV therapeutic vaccines across key target groups in 20 nations (public/private) including North America, Europe, Australia and Japan A thorough review of latest epidemiological/impact studies is presented along with discussion of vaccinology/new R&D strategies with a focus on next generation concepts. A competitor landscape is also provided with examination of the merits of mRNA approaches.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Herpes Simplex virus vaccines in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

### PRODUCT CONTENTS:

Published May 2023 (CAT No: VAMV038)

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

#### Contents – Summary presentation (.pdf)



Contents  
Author's notes

#### Executive summary

**[SECTION 1]** Herpes Simplex Virus: disease background/diagnosis/treatment  
**[SECTION 2]** Herpes Simplex Virus: review of epidemiology/interaction with HIV  
**[SECTION 3]** Herpes Simplex Virus: summary of vaccine development, current R&D  
**[SECTION 4]** Herpes Simplex Virus vaccines: modelling commercial potential WEST  
**[SECTION 5]** Herpes Simplex Virus vaccines: quantifying target populations  
**[SECTION 6]** Herpes Simplex Virus vaccines: backup and source material  
References/bibliography  
About **VacZine Analytics**  
Disclaimer

**SNAPSHOT**

**PAGES: >175 slides fully referenced/sourced. Available in .pdf form**

#### Contents – MS-Excel workbook (.xls)



United States [3 target product profiles (TPPs), LO/BASE and HI scenarios]  
Canada  
UK  
France  
Germany  
Italy  
Spain  
Other Europe\*  
Australia  
Japan



**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$12,995.00**/ GBP **£10,565.00**# (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

# - *indicative prevailing rate will be applied on date of transaction*

**HOW TO ORDER:**

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and the “**spiral logo**” are UK Registered Trademarks, 2009

## **BIBLIOGRAPHY**

References – available upon request



**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

A division of Assay Advantage Ltd  
Warren (Carlton) House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 927049  
E-mail: [info@vaczine-analytics.com](mailto:info@vaczine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and "the spiral logo" are UK Registered Trademarks, 2009



*Since 2007*

